Compare e l f Beauty Inc (ELF) vs Tango Therapeutics Inc. (TNGX) Price & Performance

ELF Beauty trades at $108.16, down 1.62% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust revenue growth, reaching $1.31B in 2025, though net margins compressed to 3.38% in 2026. Recent expansion includes rhode brand launches in Europe via Sephora and innovative marketing campaigns like the 'Mirror Mix' music album. Analyst consensus shows mixed sentiment with 48% buy ratings but a $95.91 price target below current levels.

ELF's premium valuation (P/E 110.34) reflects growth expectations but poses risk if execution falters. International expansion and brand innovation provide upside, while high debt levels and margin pressure present challenges. The stock's technical strength contrasts with fundamental valuation concerns, requiring careful monitoring of earnings delivery against elevated expectations.

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.